{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T17:54:33Z","timestamp":1762710873426,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12185-019-02606-0","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T05:50:10Z","timestamp":1549432210000},"page":"418-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II study of FLAGM (fludarabine\u2009+\u2009high-dose cytarabine\u2009+\u2009granulocyte colony-stimulating factor\u2009+\u2009mitoxantrone) for relapsed or refractory acute myeloid leukemia"],"prefix":"10.1007","volume":"109","author":[{"name":"The Japan\u00a0Adult Leukemia Study Group (JALSG)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahoko","family":"Hatsumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1173-4216","authenticated-orcid":false,"given":"Shuichi","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumihisa","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"2606_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, L\u00f6wenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487\u201394.","journal-title":"J Clin Oncol"},{"key":"2606_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453\u201374.","journal-title":"Blood"},{"key":"2606_CR3","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117:2358\u201365.","journal-title":"Blood"},{"key":"2606_CR4","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117:2366\u201372.","journal-title":"Blood"},{"key":"2606_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/sj.leu.2401568","volume":"14","author":"EH Estey","year":"2000","unstructured":"Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:476\u20139.","journal-title":"Leukemia"},{"key":"2606_CR6","first-page":"329","volume":"48","author":"V Gandhi","year":"1988","unstructured":"Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988;48:329\u201334.","journal-title":"Cancer Res"},{"key":"2606_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","volume":"11","author":"V Gandhi","year":"1993","unstructured":"Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116\u201324.","journal-title":"J Clin Oncol"},{"key":"2606_CR8","first-page":"1539","volume":"9","author":"V Gandhi","year":"1997","unstructured":"Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-d-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997;9:1539\u201345.","journal-title":"Clin Cancer Res"},{"key":"2606_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","volume":"12","author":"E Estey","year":"1994","unstructured":"Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O\u2019Brien S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671\u20138.","journal-title":"J Clin Oncol"},{"key":"2606_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3109\/10428199309148532","volume":"9","author":"E Estey","year":"1993","unstructured":"Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk lymphoma. 1993;9:343\u201350.","journal-title":"Leuk lymphoma"},{"key":"2606_CR11","unstructured":"NCCN Practice Guidelines in Oncology AML. (Version 2.2011). \n                    http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf\n                    \n                  . Accessed 24 Nov 2011."},{"key":"2606_CR12","first-page":"513","volume":"81","author":"M Clavio","year":"1996","unstructured":"Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica. 1996;81:513\u201320.","journal-title":"Haematologica"},{"key":"2606_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/10428199709068275","volume":"27","author":"TJC Nokes","year":"1997","unstructured":"Nokes TJC, Johnson S, Harvey D, Goldstone AH. FLAG is a useful regimen for poor prognosis adult myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 1997;27:93\u2013101.","journal-title":"Leuk Lymphoma"},{"key":"2606_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","volume":"99","author":"JE Parker","year":"1997","unstructured":"Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM,et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997;99:939\u201344.","journal-title":"Br J Haematol"},{"key":"2606_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W","volume":"58","author":"M Montillo","year":"1998","unstructured":"Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A,et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58:105\u20139.","journal-title":"Am J Hematol"},{"key":"2606_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s002770050541","volume":"78","author":"HT Steinmetz","year":"1999","unstructured":"Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol. 1999;78:418\u201325.","journal-title":"Ann Hematol"},{"key":"2606_CR17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00277-003-0624-2","volume":"82","author":"D Pastore","year":"2003","unstructured":"Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory\/relapsed acute myeloid leukemia: single-center experience. Ann Hematol. 2003;82:231\u20135.","journal-title":"Ann Hematol"},{"key":"2606_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1532\/IJH97.07072","volume":"86","author":"S Miyawaki","year":"2007","unstructured":"Miyawaki S, Kawai Y, Takeshita A, Komatsu N, Usui N, Arai Y, et al. Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol. 2007;86:343\u20137.","journal-title":"Int J Hematol"},{"key":"2606_CR19","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322\u201333.","journal-title":"Blood"},{"key":"2606_CR20","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"2606_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1\u201310.","journal-title":"Control Clin Trials"},{"key":"2606_CR22","first-page":"208 a","volume":"80","author":"E Feldman","year":"1992","unstructured":"Feldman E, Gandhi V, Plunkett W, Nowak B, Estey E, Kantarjian H, et al. Sequential administration of fludarabine, ara-C, and MIT enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia. Blood. 1992;80:208 a.","journal-title":"Blood"},{"key":"2606_CR23","first-page":"356","volume":"24","author":"M H\u00e4nel","year":"2001","unstructured":"H\u00e4nel M, Friedrichsen K, H\u00e4nel A, Herbst R, Morgner A, Neser S, et al. Mito-FLAG as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie. 2001;24:356\u201360.","journal-title":"Onkologie"},{"key":"2606_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/sj.leu.2401406","volume":"13","author":"JL Byrne","year":"1999","unstructured":"Byrne JL, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D, et al. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia. 1999;13:786\u201391.","journal-title":"Leukemia"},{"key":"2606_CR25","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman J, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicenter, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol. 2017;18:1061\u201375.","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02606-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T19:24:59Z","timestamp":1580930699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02606-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02606-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SM received personal fees from Astelas, Ohtsuka Pharmaceutical and Novartis Pharma K. K, outside the submitted work; AT received grants from Chugai Pharmaceutical Co., Ltd., grants from Teijin Pharma K.K., grants from Pfizer Japan Inc., grants from Astellas Pharma Inc., grants from Takeda Pharmaceutical Co.,Ltd., grants from Nihon Pharmaceutical Co.,Ltd., grants from Bristol-Myers Squibb Co., grants from Kyowa Hakko Kirin Co.,Ltd., grants from Daiichi Sankyo Co.,Ltd., grants from Japan Blood Product Organization, outside the submitted work; MO received personal fees from MundiPharma, personal fees from MeijiSeika Pharma, grants and personal fees from Celltrion, personal fees from Takeda, grants and personal fees from SymBio, personal fees from Cellgene, personal fees from AstraZeneka, outside the submitted work; NU received personal fees from Celgene Co.,Ltd, personal fees from CIMIC Co.,Ltd., personal fees from Otsuka Pharmaceutical Co.,Ltd., grants and personal fees from Pfizer Co.,Ltd., personal fees from Takeda Bio Development Center Ltd., personal fees from Kyowa Hakko Kirin Co.,Ltd., personal fees from Chugai Pharmaceutical Co.,Ltd, outside the submitted work; TN received grants and personal fees from Astellas Pharma Inc., grants from Amgen Astellas BioPharma K.K., grants and personal fees from Dainippon Sumitomo Pharma Co.,LTD., grants from Fujifilm Corporation, personal fees from Nippon Boehringer Ingelheim Co., Ltd., grants from Otsuka Pharmaceutical Co.,Ltd., grants from TOYAMA CHEMICAL CO.,LTD., outside the submitted work; In addition, TN has a patent Fujifilm Corporation issued, a patent Chugai Pharmaceutical Co.,LTD. issued, and a patent Kyowa-Hakko Kirin Co.,Ltd. issued. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}